{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:51:19Z","timestamp":1788522679272,"version":"build-2803163510"},"reference-count":60,"publisher":"Baishideng Publishing Group Inc.","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastroenterol"],"abstract":"<jats:p>In this editorial, we comment on the article by Chen et al . Metabolic dysfunction-associated fatty liver disease (MAFLD) is a global public health burden whose incidence has risen concurrently with overweight and obesity. Given its detrimental health impact, early identification of at-risk individuals is crucial. MAFLD diagnosis is based on evidence of hepatic steatosis indicated by liver biopsy, imaging, or blood biomarkers, and one of the following conditions: Overweight\/obesity, type 2 diabetes mellitus, or metabolic dysregulation. However, in large-scale epidemiological studies, liver biopsies are not feasible. The application of techniques such as ultrasonography, computed tomography, magnetic resonance imaging, and magnetic resonance spectroscopy is restricted by their limited sensitivity, low effectiveness, high costs, and need for specialized software. Blood biomarkers offer several advantages, particularly in large-scale epidemiological studies or clinical scenarios where traditional imaging techniques are impractical. Analysis of cumulative effects of excess high-normal blood alanine aminotransferase (ALT) levels of blood ALT levels could facilitate identification of at-risk patients who might not be detected through conventional imaging methods. Accordingly, investigating the utility of blood biomarkers in MAFLD should enhance early detection and monitoring, enabling timely intervention and management and improving patient outcomes.<\/jats:p>","DOI":"10.3748\/wjg.v30.i25.3132","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T02:11:47Z","timestamp":1719799907000},"page":"3132-3139","source":"Crossref","is-referenced-by-count":11,"title":["Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease"],"prefix":"10.3748","volume":"30","author":[{"given":"Di","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Xiong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438","DOI":"10.1016\/S0025-6196(24)00530-5"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011775"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.02.030"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.038"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056260"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-421"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2019.07.008"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19069"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.09.001"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.042"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.22775"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50229"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1024836"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02290-1"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S389794"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15799"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"B22","unstructured":"Non-Alcoholic Fatty Liver Disease: Assessment and Management. London: National Institute for Health and Care Excellence (NICE); 2016 Jul-"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13857"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i30.3361"},{"key":"B25","unstructured":"Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. Gastroenterol Hepatol (N Y) 2019; 15: 357-365"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.666"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1010"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.003"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27395"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.10.002"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2017.10.001"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-12926"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07486.x"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00012"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.14744\/hf.2020.2020.0012"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cld.728"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154455"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.017"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14284"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.02.014"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.031"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00170.2018"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10121-2"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1075-y"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100284"},{"key":"B48","unstructured":"Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop Gastroenterol 2004; 25: 130-134"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-1165-z"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i10.1346"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1593"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1794"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-023-00789-5"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.10.014"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2016.1154516"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50004"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2011.300452"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.138"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12226"},{"key":"B60","unstructured":"Chen JF, Wu ZQ, Yan S, Wang YX, Song XQ, Ding SY. [The bidirectional relationship between long-term dynamic alanine aminotransferase level and metabolic associated fatty liver disease]. Zhonghua Neifenmi Daixie Zazhi 2023; 39: 1028-1036"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v30\/i25\/3132.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v30\/i25\/3132.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T04:01:45Z","timestamp":1732334505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1007-9327\/full\/v30\/i25\/3132.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,7]]},"references-count":60,"journal-issue":{"issue":"25"},"URL":"https:\/\/doi.org\/10.3748\/wjg.v30.i25.3132","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,7]]}}}